MedTrace Logo

A Study of ARC-02 in B-cell NHL

NCT07691606 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2026-07-28

No results posted yet for this study

Summary

This study is to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of ARC-02.

Conditions

  • B-cell Non Hodgkin Lymphoma

Interventions

DRUG

ARC-02

Intravenous (IV) infusion.

DRUG

Rituximab

IV infusion.

Sponsors & Collaborators

  • Taiho Oncology, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-22
Primary Completion
2029-01-31
Completion
2030-12-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • France
  • Italy
  • Poland
  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07691606 on ClinicalTrials.gov